Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treating Uncomplicated Malaria: A Randomized Trial to Guide Policy in Uganda

@article{Yeka2008ArtemetherLumefantrineVD,
  title={Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treating Uncomplicated Malaria: A Randomized Trial to Guide Policy in Uganda},
  author={Adoke Yeka and G. Dorsey and M. Kamya and A. Talisuna and M. Lugemwa and J. Rwakimari and S. Staedke and P. Rosenthal and F. Wabwire-mangen and H. Bukirwa},
  journal={PLoS ONE},
  year={2008},
  volume={3}
}
Background Uganda recently adopted artemether-lumefantrine (AL) as the recommended first-line treatment for uncomplicated malaria. However, AL has several limitations, including a twice-daily dosing regimen, recommendation for administration with fatty food, and a high risk of reinfection soon after therapy in high transmission areas. Dihydroartemisinin-piperaquine (DP) is a new alternative artemisinin-based combination therapy that is dosed once daily and has a long post-treatment prophylactic… Expand
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children.
TLDR
Artemether-lumefantrine and dihydroartemisinin-piperaquine were both efficacious and had similar long-term effects on the risk of recurrent malaria. Expand
Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Ugandan Children
TLDR
AL and DHA-PQ remain effective for the treatment of malaria in Uganda and neither regimen selected for genetic polymorphisms associated with drug resistance. Expand
Efficacy of Quinine, Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine as Rescue Treatment for Uncomplicated Malaria in Ugandan Children
TLDR
Recurrent infections observed after the administration of an ACT can be successfully treated with an alternative ACT rather than with quinine, as shown in a nested, randomized, open label, three-arm clinical trial of rescue therapy in children with recurrent malaria infection. Expand
Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children
TLDR
Both AL and DP were safe and well tolerated for the treatment of uncomplicated malaria in young HIV-infected and uninfected children. Expand
Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Plasmodium falciparum Malaria in Children Aged Less than 15 Years in Guinea-Bissau – An Open-Label Non-Inferiority Randomised Clinical Trial
TLDR
Artemether-lumefantrine was not inferior to DP for treatment of uncomplicated P. falciparum malaria in Guinea-Bissau and both treatments achieved the WHO recommended efficacy for antimalarials about to be adopted as policy. Expand
Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial
TLDR
DHA-PQP is as efficacious as AL in treating uncomplicated malaria in African children from different endemicity settings, and shows a comparable safety profile. Expand
Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial.
TLDR
AS/AQ treatment was followed by fewer recurrences than AL treatment, contrasting with older data, and research should consider multiple or rotating regimens to maintain treatment efficacies. Expand
Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated falciparum Malaria Reduce the Risk for Recurrent New falciparum Infection More Than Artemether-Lumefantrine?
TLDR
It is concluded that use of DP offers superior posttreatment prophylaxis compared to AL in the study areas and can help reduce malaria cases in such areas more than AL. Expand
Dihydroartemisinin–piperaquine versus artemether–lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan
TLDR
Both treatments appeared effective and safe for the treatment of uncomplicated P. falciparum malaria in central Sudan, although treatment with DHA–P (which requires a simpler dosing regimen) might be preferred to treatment with AL. Expand
Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial
TLDR
Both ASAQ and AL are highly effective and currently adequate as the first-line treatment of uncomplicated falciparum malaria in this area of Katanga, DRC, however, surveillance of efficacy of artemisinin-based combination treatments, including other evaluations of the resistance of ASAQ, need to be done in other provinces. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 25 REFERENCES
Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial
TLDR
DP was superior to AL for reducing the risk of recurrent parasitemia and gametocytemia, and provided improved hemoglobin recovery, and appears to be a good alternative to AL as first-line treatment of uncomplicated malaria in Uganda. Expand
Artemisinin versus Nonartemisinin Combination Therapy for Uncomplicated Malaria: Randomized Clinical Trials from Four Sites in Uganda
TLDR
A AQ + AS was the most efficacious regimen for preventing recrudescence, but this benefit was outweighed by an increased risk of new infection. Expand
Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial
TLDR
Sulfadoxine/pyrimethamine plus amodiaquine could be used as an inexpensive regimen to decrease the rate of subsequent episodes of malaria. Expand
Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso.
  • I. Zongo, G. Dorsey, +4 authors J. Ouédraogo
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2007
TLDR
Considering the risks of recurrent malaria after therapy, the amodiaquine plus sulfadoxine-pyrimethamine and dihydroartemisinin-piperaquine regimens were more efficacious than the artemether-lumefantrine regimen (the new national regimen in Burkina Faso) for the treatment of uncomplicated P. falciparum malaria. Expand
Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.
TLDR
Both treatments were highly efficacious, but AL provided stronger prevention against reinfection and the genetic selection by the long-acting partner drug underlines the importance of long follow-up periods in clinical trials. Expand
Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand.
TLDR
The current dosage of DP given over the course of 48 h is highly effective, safe, and well tolerated for the treatment of multidrug-resistant falciparum malaria, and its efficacy is not improved by the addition of more DHA. Expand
Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children.
TLDR
A 3-day treatment with DHA-PQP proved to be efficacious with a good safety and tolerability profile and could be a good candidate for the next first-line treatment for malaria in Rwanda. Expand
Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria in Uganda
TLDR
Artemether–lumefantrine was superior to amodiaquine + artesunate for prevention of new infections and frequent repeated therapy on the efficacy, safety, and cost-effectiveness of new artemisinin regimens should be further investigated. Expand
Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial
TLDR
Dihydroartemisinin-piperaquine is an inexpensive, safe, highly efficacious fixed-dose antimalarial combination treatment that could make an important contribution to the control of multidrug-resistant falciparum malaria. Expand
Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial
TLDR
Artemether-lumefantrine has a high cure rate irrespective of whether given under supervision with food or under conditions of routine clinic practice, and could make a substantial contribution to malaria control in Africa. Expand
...
1
2
3
...